Infusions, Intravenous

16 trials

Sponsors

Hida Yasuhiro, Akihito Tanaka, Center of Molecular Immunology (CIM), Center of Molecular Immunology(CIM), Cancerology State Institute, Colima State Health Service (SSA-Colima), Mexico

Conditions

Acute asthmaAdvanced breast cancerCD20+ B-cell non-Hodgkin lymphoma of Low-Grade (Follicular or small lymphocytic lymphoma ) or aggressive (Diffuse large B-cell lymphoma (DLBCL) or Follicular stage III-IV.COVID-19 COVID-19 SARS-CoV2COVID-19 COVID-19 SARS-CoV-2COVID-19 COVID-19 SARS-CoV2Cardiovascular, renal and respiratory disorders in convalescent patients from SARS-CoV-2 infection COVID-19 SARS-CoV2Castration resistant prostate cancer

Phase 1

Advanced breast cancer treatment with hR3 monoclonal antibody combined with doxorubicin and cyclophosphamide, phase I.

Active, not recruitingRPCEC00000057

Center of Molecular Immunology (CIM)Advanced breast cancer

Start: 2005-10-13Target: 15Updated: 2026-03-30

Homeostec for the treatment of chronic Chikungunya

Active, not recruitingRPCEC00000226

Cancerology State Institute, Colima State Health Service (SSA-Colima), MexicoChronic Joint Disease Caused by Chikungunya Virus

Start: 2017-01-10Target: 20Updated: 2026-03-30

Anti SARS-CoV-2 gammaglobulin

Active, not recruitingRPCEC00000379

AICA Laboratorories CompanyCOVID-19 COVID-19 SARS-CoV2

Start: 2021-07-01Target: 30Updated: 2026-03-30

Phase 2

1E10 anti-idiotype vaccine, metastatic colon, phase II.

Active, not recruitingRPCEC00000006

Center of Molecular Immunology (CIM)Colon adenocarcinoma phase IV or evolvable metastatic disease

Start: 2002-07-19Target: 40Updated: 2026-03-30

h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin.

Active, not recruitingRPCEC00000014

Center of Molecular Immunology(CIM)Non-surgical malignant esophagus tumors.

Start: 2005-12-14Target: 68Updated: 2026-03-30

ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders

Active, not recruitingRPCEC00000376

Center of Molecular Immunology (CIM)Cardiovascular, renal and respiratory disorders in convalescent patients from SARS-CoV-2 infection COVID-19 SARS-CoV2

Start: 2022-01-07Target: 135Updated: 2026-03-30

Phase 3

Homeostec for chronic arthritis

Active, not recruitingRPCEC00000249

Cancerology State Institute, Colima State Health Service (SSA-Colima), MexicoChronic arthritis for Chikungunya

Start: 2017-12-04Target: 50Updated: 2026-03-30

CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial

Active, not recruitingRPCEC00000291

Center of Molecular Immunology (CIM)Castration resistant prostate cancer

Start: 2018-10-01Updated: 2026-03-30

Prevention of metastasis by an ultra-short acting and the most selective beta1 blocker, Landiolol

Active, not recruitingJPRN-jRCT2011180004

Hida Yasuhironon-small cell lung cancer non-small cell lung cancer

Start: 2019-01-23Target: 400Updated: 2025-07-18

RecruitingJPRN-jRCT2041230037

Akihito TanakaMembranous nephropathy Glomerulonephritis, Membranous

Start: 2023-06-24Target: 88Updated: 2025-07-18

Phase 4

Nimotuzumab-pancreatic cancer-adults-Phase IV.

RecruitingRPCEC00000245

Center of Molecular ImmunologyPancreatic cancer locally advanced unresectable or metastatic

Start: 2017-05-15Updated: 2026-03-30

CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma

Active, not recruitingRPCEC00000251

Center of Molecular ImmunologyCD20+ B-cell non-Hodgkin lymphoma of Low-Grade (Follicular or small lymphocytic lymphoma ) or aggressive (Diffuse large B-cell lymphoma (DLBCL) or Follicular stage III-IV.

Start: 2017-10-01Updated: 2026-03-30

Unknown Phase

Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab

RecruitingRPCEC00000311

Center of Molecular Immunology (CIM)severe SARS-CoV-2 pneumonia COVID-19 SARS-CoV-2

Start: 2020-03-28Target: 80Updated: 2026-03-30

Second Line-Acute Asthma

Active, not recruitingRPCEC00000324

Autonomous Service Antonio Patricio de Alcalá University Hospital (SAHUAPA)Acute asthma

Start: 2017-04-01Target: 131Updated: 2026-03-30

Itolizumab Safety and Efficacy Study in Covid 19

Active, not recruitingRPCEC00000361

Center of Molecular Immunology(CIM)COVID-19 COVID-19 SARS-CoV-2

Start: 2021-04-01Target: 20Updated: 2026-03-30

Itolizumab-Plasmapheresis in patients with COVID-19

Active, not recruitingRPCEC00000380

Center of Molecular ImmunologyCOVID-19 COVID-19 SARS-CoV2

Start: 2021-09-27Target: 50Updated: 2026-03-30

Related Papers

Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol

PLoS ONE2025-03-18

Nimotuzumab Concurrent with Gemcitabine as First‐Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma

BioMed Research International2023-01-012 citations

Treatment of Systemic Inflammation with Itolizumab: A Single Center Experience

Archives of Clinical and Medical Case Reports2022-01-01

Safety and efficacy of a COVID‑19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open‑label, controlled trial

Experimental and Therapeutic Medicine2021-06-2927 citations

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.

2020-11-1420 citations

Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients.

2019-12-118 citations